LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII

Oncogene

Volumn 27, Issue 43, 2008, Pages 5741-5752

  Stutz, M A ^a   Shattuck, D L ^a   Laederich, M B ^a,b   Carraway III, K L ^a   Sweeney, C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

EGFRvIII; Glioblastoma; LRIG1; Negative regulator

Indexed keywords

CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN PROTEIN 1; MUTANT PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; GENE OVEREXPRESSION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; REGULATORY MECHANISM; RNA INTERFERENCE; WILD TYPE;

APOPTOSIS; GLIOBLASTOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 52949087545     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.185     Document Type: Article

References (34)

1. Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S et al. (2005). Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24: 4540-4548.
2. Aoki T, Hashimoto N, Matsutani M. (2007). Management of glioblastoma. Expert Opin Pharmacother 8: 3133-3146.
3. Cook PW, Piepkorn M, Clegg CH, Plowman GD, DeMay JM, Brown JR et al. (1997). Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 100: 2286-2294.
4. Davies GC, Ryan PE, Rahman L, Zajac-Kaye M, Lipkowitz S. (2006). EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins. Oncogene 25: 6497-6509.
5. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pantè G, Amann K et al. (2006). Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 12: 568-573.
6. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C et al. (2007). A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 26: 368-381.
7. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS. (2007). EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 7: 1408-1417.
8. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J et al. (2004). LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23: 3270-3281.
9. Han W, Zhang T, Yu H, Foulke JG, Tang CK. (2006). Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther 5: 1361-1368.
10. Hedman H, Nilsson J, Guo D, Henriksson R. (2002). Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 41: 352-354..
11. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD et al. (1997). The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927-2935.
12. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK et al. (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104: 12867-12872.
13. Kirisits A, Pils D, Krainer M. (2007). Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. Int J Biochem Cell Biol 39: 2173-2182.
14. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway III KL et al. (2004). The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050-47056.
15. Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH et al. (2004). Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10: 3216-3224.
16. Lindström AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H et al. (2008). LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 18: 312-317.
17. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024.
18. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ. (1998). Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273: 200-206.
19. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. (1998). Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95: 5724-5729.
20. Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK et al. (2001). Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95: 472-479.
21. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. (2006). Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12: 7261-7270.
22. Peschard P, Kozlov G, Lin T, Mirza IA, Berghuis AM, Lipkowitz S et al. (2007). Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. Mol Cell 27: 474-485.
23. Raizer JJ. (2005). HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 74: 77-86.
24. Rosell R, Taron M, Reguart N, Isla D, Moran T. (2006). Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 12: 7222-7231.
25. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway III KL et al. (2007). LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 27: 1934-1946.
26. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. (2007). The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75: 770-787.
27. Sweeney C, Miller JK, Shattuck D, Carraway III KL. (2006). ErbB receptor negative regulatory mechanisms: implications in cancer. J Mammary Gland Biol Neoplasia 11: 89-99.
28. Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, Sano S et al. (2002). Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett 521: 67-71.
29. Tanemura A, Nagasawa T, Inui S, Itami S. (2005). LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423-430.
30. Thomasson M, Hedman H, Guo D, Ljungberg B, Henriksson R. (2003). LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Br J Cancer 89: 1285-1289.
31. Vassar R, Fuchs E. (1991). Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev 5: 714-727.
32. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM et al. (2006). Mammalian target of rapamycin inhibition promotes responses to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblasma cells. Cancer Research 66: 7864-7869.
33. Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A et al. (2002). A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 21: 303-313.
34. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG. (1990). Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 247: 962-964.